Article

Better UCVA results, less dry eye seen in early postop period

San Diego-When compared with standard mechanical microkeratome treatments, the results following both wavefront-guided custom and standard laser treatments with the IntraLase femtosecond laser (IntraLase Corp.) were found to be statistically significantly superior in the early postoperative period.

The uncorrected visual acuity (UCVA) levels after the procedure with Alcon custom and standard treatments were better with the IntraLase compared with similar treatments with the Hansatome microkeratome (Bausch & Lomb) at all time points for visual acuity levels, and there were less dry eye findings in the eyes treated with IntraLase, Daniel S. Durrie, MD, reported at the annual meeting of the American Society of Cataract and Refractive Surgery.

In the study, 51 patients underwent Alcon CustomCornea treatment and 37 patients had standard Alcon LadarVision 4000 treatment. One eye of each patient had the LASIK flap made with the Hansatome micro keratome (Bausch & Lomb) and the other eye had the flap made with the IntraLase femtosecond laser.

The better uncorrected vision was not due to a need for a nomogram adjustment. The accuracy of the treatment was the same. One month after surgery, the mean spherical equivalent was similar in both groups. In the IntraLase eyes the average sphere was -0.14 ± 0.24 D compared with -0.26 ± 0.30 D for the Hansatome (p = 0.016) and the cylinder measurements, respectively, were -0.14 ± 0.21 D and -0.26 ± 0.27 D (p = 0.007). Six months after surgery, the spherical equivalents were -0.29 ± 0.28 D and -0.33 ± 0.32 D, respectively (p = 0.21) and the cylinder -0.19 ± 0.23 D and -0.26 ± 0.27 D (p = 0.12).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.